Vasodilators in acute heart failure - evidence based on new studies

被引:11
作者
Travessa, Andre M.
Falcao, L. Menezes [1 ]
机构
[1] Ctr Hosp Lisboa Norte, Av Prof Egas Moniz, P-1649035 Lisbon, Portugal
关键词
Acute heart failure; Vasodilators; Clinical trials; Mortality; Outcomes; Pharmacologic therapy; GUANYLATE-CYCLASE ACTIVATOR; ACUTE MYOCARDIAL-INFARCTION; LEFT-VENTRICULAR FAILURE; DOUBLE-BLIND; BLOOD-PRESSURE; INTRAVENOUS ISOSORBIDE-5-MONONITRATE; SODIUM-NITROPRUSSIDE; ISOSORBIDE DINITRATE; NATRIURETIC PEPTIDE; TYPE-1; RECEPTOR;
D O I
10.1016/j.ejim.2018.02.020
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Acute heart failure (AHF) contributes largely to the worldwide burden of heart failure (HF) and is associated with high mortality, poor prognosis and high rehospitalization rate. The pharmacologic therapy of AHF includes diuretics and vasodilators, which are a keystone when fluid overload and congestion are present. However, vasodilators are mainly focused on controlling symptoms, and drugs that also improve long-term mortality and morbidity seem to be in high demand. In this review, we summarize the existing evidence on mortality benefits of IV vasodilators in AHF. There is lack of evidence on the mortality benefits of IV vasodilators in AHF, as well as well-designed and large-scale trials for some of them. The existing trials on nitrates have conflicting results and are insufficient to establish definitive conclusions. Other vasodilators, such as enalaprilat, clevidipine, carperitide, and ularitide, have been evaluated only in a few trials assessing mortality. Levosimendan, nesititide and carperitide are approved by some regulatory agencies; however, data regarding mortality are also conflicting and large-scale postmarketing studies would be important. Serelaxin is a recent therapy with a novel mechanism of action and seemed to be promising; although serelaxin was safe and well tolerated in earlier trials, the results of a larger phase III trial failed to meet the primary endpoints of reduction in cardiovascular death at day 180 and reduction of worsening heart failure at day 5. The absence of definitive mortality benefits and high-quality and large-scale data not allow firm conclusions to be drawn about the role of IV vasodilators in AHF. Well-designed studies are needed to clarify the role of these drugs in the long-term outcome of AHF, as well as new therapies entering the clinical investigation.
引用
收藏
页码:1 / 10
页数:10
相关论文
共 71 条
[51]   Clevidipine in acute heart failure: Results of the A Study of Blood Pressure Control in Acute Heart Failure-A Pilot Study (PRONTO) [J].
Peacock, W. Frank ;
Chandra, Abhinav ;
Char, Douglas ;
Collins, Sean ;
Sahakian, Guillaume Der ;
Ding, Li ;
Dunbar, Lala ;
Fermann, Gregory ;
Fonarow, Gregg C. ;
Garrison, Norman ;
Hu, Ming-yi ;
Jourdain, Patrick ;
Laribi, Said ;
Levy, Phillip ;
Moeckel, Martin ;
Mueller, Christian ;
Ray, Patrick ;
Singer, Adam ;
Ventura, Hector ;
Weiss, Mason ;
Mebazaa, Alex .
AMERICAN HEART JOURNAL, 2014, 167 (04) :529-536
[52]   The Role of Intravenous Vasodilators in Acute Heart Failure Management [J].
Piper, Susan ;
McDonagh, Theresa .
EUROPEAN JOURNAL OF HEART FAILURE, 2014, 16 (08) :827-834
[53]   Bolus versus continuous low dose of enalaprilat in congestive heart failure with acute refractory decompensation [J].
Podbregar, M ;
Voga, G ;
Horvat, M ;
Zuran, I ;
Krivec, B ;
Skale, R ;
Pareznik, R .
CARDIOLOGY, 1999, 91 (01) :41-49
[54]   2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure [J].
Ponikowski, Piotr ;
Voors, Adriaan A. ;
Anker, Stefan D. ;
Bueno, Hector ;
Cleland, John G. F. ;
Coats, Andrew J. S. ;
Falk, Volkmar ;
Ramon Gonzalez-Juanatey, Jose ;
Harjola, Veli-Pekka ;
Jankowska, Ewa A. ;
Jessup, Mariell ;
Linde, Cecilia ;
Nihoyannopoulos, Petros ;
Parissis, John T. ;
Pieske, Burkert ;
Riley, Jillian P. ;
Rosano, Giuseppe M. C. ;
Ruilope, Luis M. ;
Ruschitzka, Frank ;
Rutten, Frans H. ;
van der Meer, Peter .
EUROPEAN HEART JOURNAL, 2016, 37 (27) :2129-U130
[55]   A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure [J].
Ponikowski, Piotr ;
Mitrovic, Veselin ;
Ruda, Mikhail ;
Fernandez, Alberto ;
Voors, Adriaan A. ;
Vishnevsky, Alexander ;
Cotter, Gad ;
Milo, Olga ;
Laessing, Ute ;
Zhang, Yiming ;
Dahlke, Marion ;
Zymlinski, Robert ;
Metra, Marco .
EUROPEAN HEART JOURNAL, 2014, 35 (07) :431-441
[56]  
Potter Lincoln R., 2009, V191, P341, DOI 10.1007/978-3-540-68964-5_15
[57]   Efficacy and safety of levosimendan in patients with acute right heart failure: A meta-analysis [J].
Qiu, Jiayong ;
Jia, Lei ;
Hao, Yingying ;
Huang, Shenshen ;
Ma, Yaqing ;
Li, Xiaofang ;
Wang, Min ;
Mao, Yimin .
LIFE SCIENCES, 2017, 184 :30-36
[58]   HEMODYNAMIC-EFFECTS OF INTRAVENOUS ISOSORBIDE-5-MONONITRATE IN ACUTE AND CHRONIC LEFT HEART-FAILURE OF ISCHEMIC ETIOLOGY [J].
RABINOWITZ, B ;
KATZ, A ;
SHOTAN, A ;
CHOURAQUI, P ;
NEUFELD, HN .
EUROPEAN HEART JOURNAL, 1988, 9 :175-180
[59]   INTRAVENOUS ISOSORBIDE-5-MONONITRATE IN THE TREATMENT OF ACUTE MYOCARDIAL-INFARCTION [J].
REZAKOVIC, DE ;
GOLDNER, V ;
BATINIC, Z ;
WEISS, M ;
STALEC, J ;
PAVICIC, L .
AMERICAN JOURNAL OF CARDIOLOGY, 1990, 65 (21) :J50-J56
[60]   Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure [J].
Sackner-Bernstein, JD ;
Skopicki, HA ;
Aaronson, KD .
CIRCULATION, 2005, 111 (12) :1487-1491